CDH11 and breast carcinoma: In breast cancer specimens, more than half of the cases exhibited strong and moderate positivity for CDH11, ILF3 or HOXC8, and only a few cases were negative for CDH11, ILF3 or HOXC8 (7.9% for CDH11, 13.2% for ILF3, and 13.2% for HOXC8).